AstraZeneca gets DCGI approval for Osimertinib tablets

Osimertinib 40mg/80mg film-coated tablets as monotherapy is now approved for additional indication

77
DCGI CDSCO

Last Updated on March 13, 2021 by The Health Master

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India (DCGI) for Osimertinib 40mg/80mg film-coated tablets (Tagrisso).

Osimertinib 40mg/80mg film-coated tablets as monotherapy is now approved for additional indication for the adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon19 deletions or exon 21 (L858R) substitution mutations.

The receipt of this permission paves way for the launch of Osimertinib 40mg/80 mg film-coated tablets into a new disease area in India, subject to the receipt of related statutory approvals and licenses.


Also read:

Lupin launches generic Nitazoxanide tablets

Dr Reddy’s gets 3 observations from USFDA for US-based API plant

World’s most expensive drug, costs ₹18 crore per dose

NATCO gets USFDA nod for Breast Cancer treatment drug

Kite gets USFDA nod for drug to treat Follicular Lymphoma

Shilpa Medicare gets USFDA tentative nod for drug for Arthritis

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner